Ahn, Daniel H.
Uson Junior, Pedro Luiz Serrano
Masci, Peter
Kosiorek, Heidi
Halfdanarson, Thorvardur R.
Mody, Kabir
Babiker, Hani
DeLeon, Thomas
Sonbol, Mohamad Bassam
Gores, Gregory
Smoot, Rory
Bekaii-Saab, Tanios
Mahipal, Amit
Mansfield, Aaron
Tran, Nguyen H.
Hubbard, Joleen M.
Borad, Mitesh J.
Article History
Received: 21 July 2021
Accepted: 26 August 2021
First Online: 31 August 2021
Declarations
:
: The study was approved by the Mayo Clinic Institutional Review Board (IRB).
: All participants provided informed consent as outlined in the manuscript.
: All authors approved the final version of this manuscript.
: MJB has received grant to institution from Senhwa Pharmaceuticals, Adaptimmune, Agios Pharmaceuticals, Halozyme Pharmaceuticals, Five Prime Pharmaceuticals, Celgene Pharmaceuticals, EMD Merck Serono, Toray, Dicerna, Taiho Pharmaceuticals, Sun Biopharma, Isis Pharmaceuticals, Redhill Pharmaceuticals, Boston Biomed, Basilea, Incyte Pharmaceuticals, Mirna Pharmaceuticals, Medimmune, Bioline, Sillajen, ARIAD Pharmaceuticals, PUMA Pharmaceuticals, Novartis Pharmaceuticals, QED Pharmaceuticals, Pieris Pharmaceuticals, consultancy from ADC Therapeutics, Exelixis Pharmaceuticals, Inspyr Therapeutics, G1 Therapeutics, Immunovative Therapies, OncBioMune Pharmaceuticals, Western Oncolytics, Lynx Group, and travel support from Astra Zeneca.